Startups
(CSE: PHRM; OTCQB: PHRRF) is a specialty pharmaceutical company focused on personalized medicines, specifically peptides and psychedelics.
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 13, 2026 | 3D Printed Medicine: The Dawn of Personalized Pharmaceuticals | Personalized 3D printed medicine is here. MB Therapeutics gained French approval for GMP cartridge production, standardizing feedstock for hospital pharmacies. PharmaTher launches CraftMake printers for North America, targeting custom rare ... |
| Oct 12, 2026 | PharmaTher Builds Network of 3D Printing Nodes for Rare Disease, Shortage and Emergency Medicines | Where is AI unlocking advantages? Explore what is possible at AMA: Software 2026. Canadian specialty pharmaceutical company PharmaTher Holdings has launched the M3DICINES National Network Program, an initiative to build a distributed networ... |
| Oct 8, 2026 | PharmaTher Sets 3D Printed Medicine Roadmap, Targeting First CraftMake Orders This Quarter and a Rare Pediatric NDA by 2028 | Where can AI actually help your print workflow? Find out at AMA: Software, online on October 22nd. Specialty pharmaceutical company PharmaTher Holdings plans to take its first orders for the CraftMake pharmaceutical 3D printer in Q4 2026, t... |
| Aug 7, 2026 | Craft Health’s CraftMake Platform Gets a Peptide Test Run | Specialty pharmaceutical company PharmaTher Holdings is collaborating with Craft Health Pte. Ltd., a Singapore-based pharmaceutical technology company, to test whether Craft Health’s CraftMake 3D printing platform can produce personalized p... |
| Feb 2, 2023 | PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome | /EIN News/ -- PharmaTher’s 5th FDA orphan drug designation for KETARX™ (ketamine) Phase 2 clinical study results to support proposed Phase 3 development of KETARX™ (ketamine) to treat Rett Syndrome for FDA approval via the 505(b)(2) regulat... |
Reviews 0
FAQ about PharmaTher Holdings
What has the press written about PharmaTher Holdings?
Parsers VC has collected 6 articles mentioning PharmaTher Holdings, among them “3D Printed Medicine: The Dawn of Personalized Pharmaceuticals” (Oct 13, 2026) and “PharmaTher Builds Network of 3D Printing Nodes for Rare Disease, Shortage and Emergency Medicines” (Oct 12, 2026).
Is PharmaTher Holdings still active?
Yes, PharmaTher Holdings is active; its latest activity on Parsers VC dates from Nov 3, 2026.